title: [Efficacy and safety of sugammadex (Org 25969) in reversing moderate neuromuscular block induced by rocuronium or vecuronium in Japanese patients].
abstract: BACKGROUND
  Efficacy and safety of sugammadex in reversing neuromuscular block induced by rocuronium or vecuronium were investgated in Japanese patients.
  
  
  METHODS
  We studied 98 Japanese patients undergoing surgery requiring general anesthesia. Patients were allocated randomly to receive intubation dose of rocuronium or vecuronium. During surgery, patients received additional doses of rocuronium or vecuronium for maintenance of moderate block. At T2 reappearance sugammadex 0-4.0 mg . kg-1 was administered. The neuromuscular block was monitored with acceleromyography using TOF stimuli. Sevoflurane was administered to all treatment groups after intubation.
  
  
  RESULTS
  For the rocuronium-induced neuromuscular block, the mean recovery time of the T4/T1 ratio to 0.9 decreased from 82.1 min in the placebo group to 1.8 min in the 4.0 mg . kg-1 sugammadex group. For the vecuronium-induced neuromuscular block, it decreased from 83.2 min in the placebo group to 2.1 min in the sugammadex 4.0 mg . kg-1 group. Plasma concentrations of sugammadex were approximately dose proportional over the dose range of 0.5 to 4.0 mg . kg-1 and independent of the neuromuscular blocking agents used. No clinical evidence of recurarization or residual curarization was observed.
  
  
  CONCLUSIONS
  The efficacy and safety of sugammadex were confirmed in Japanese surgical patients.
authors.forename: Junzo
authors.initials: J
authors.lastname: Takeda
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Iwasaki
authors.forename: Michiaki
authors.initials: M
authors.lastname: Yamakage
authors.forename: Makoto
authors.initials: M
authors.lastname: Ozaki
authors.forename: Miwako
authors.initials: M
authors.lastname: Kawamata
authors.forename: Yoshio
authors.initials: Y
authors.lastname: Hatano
authors.forename: Toshihiro
authors.initials: T
authors.lastname: Yorozuya
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Miyakawa
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Kanmura
mesh_terms: D000328:Adult; D000732:Androstanols / Q000008:administration & dosage / Q000037:antagonists & inhibitors*; D000762:Anesthesia Recovery Period; D000768:Anesthesia, General; D044466:Asian People; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D019148:Neuromuscular Blockade; D003473:Neuromuscular Nondepolarizing Agents / Q000008:administration & dosage / Q000037:antagonists & inhibitors*; D000077123:Rocuronium; D000077122:Sugammadex; D014673:Vecuronium Bromide / Q000008:administration & dosage / Q000037:antagonists & inhibitors*; D055815:Young Adult; D047408:gamma-Cyclodextrins / Q000008:administration & dosage / Q000494:pharmacology*
chemical_list: D000732:Androstanols; D003473:Neuromuscular Nondepolarizing Agents; D047408:gamma-Cyclodextrins; D000077122:Sugammadex; D014673:Vecuronium Bromide; D000077123:Rocuronium